RENO, NEVADA Mar. 10, 2023 /PRNewswire/ – Sarcomatrix acquired rhLaminin-111 as a potential treatment for LAMA2-Related Dystrophies, a rare, life-threatening disease that causes respiratory insufficiency, poor muscle tone, muscle atrophy, scoliosis, and joint problems as well as delayed development of motor skills in children, from Prothelia, Inc.
“We are excited to bring the innovative science behind laminin-111 to Sarcomatrix,” said Ryan Wuebbles, Ph.D., Chief Science Officer, and global head of discovery research, Sarcomatrix. “This acquisition will deliver new capabilities to enhance our muscular dystrophy research activities, an opportunity to strengthen our portfolio, and provide a strong foothold for expanded research efforts in muscle wasting diseases like muscular dystrophy.
Sarcomatrix is committed to developing Laminin-111 as a potential treatment for LAMA2-Related Dystrophies and is seeking funding to complete the pre-clinical work and advance the program to human studies as soon as reasonably possible.
Sarcomatrix Therapeutics Corp. is a biopharmaceutical company pioneering novel therapeutics that leverage our understanding of muscle biology and tissue regeneration to develop therapies for muscle wasting diseases with high unmet needs. Our current focus is muscular dystrophies.
Sarcomatrix fully engages the patient community at each step of the drug development process and looks forward to partnering with patient advocacy groups like Cure CMD and PPMD to keep the community informed. We’d also like to thank all community members that participated in the “Retrospective Early Natural History of LAMA2-Related Dystrophies” study conducted by the folks at Cure CMD and Neuromuscular and Neurogenetic Disorders of Childhood Section, NINDS, National Institutes of Health; which was partially funded by Prothelia.